Identifying the right patient

for triplet therapy

Use NUBEQA®, the only ARPI with Swissmedic approval** and reimbursement
#
by the health insurance company in the triplet setting(3)

comparison triplet therapy

** Swissmedic approval without volume/risk restriction: NUBEQA®, in combination with docetaxel and ADT, is indicated for the treatment of adult patients with mHSPC for whom docetaxel therapy is indicated.3

# Extract from the specialty list: NUBEQA®, in combination with docetaxel and ADT, is reimbursed for the treatment of adult patients with highvolume/high-risk mHSPC for whom docetaxel therapy is indicated (ECOG PS ≤1).6

ARPI = androgen receptor pathway inhibitor

    ARASENS study shows overall survival irrespective of patient’s age
    ARASENS study shows overall survival irrespective of patient’s age chart 2

    The results support the use of darolutamide in combination with ADT and docetaxel in all patients with mHSPC, regardless of age
    13

    When intensifying treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC), it is essential to consider multiple factors related to the patient, tumour, and metastasis characteristics.1

     

    Triplet therapy with Nubeqa®

    Patients with high-volume and de novo metastatic hormone-sensitive prostate cancer can benefit from triplet therapy when their individual circumstances are taken into account, highlighting the importance of a personalized treatment approach.1

    Overall survival of patient with high-volume mHSPC

Evaluating Drug-Drug-Interactions – supporting material

mHSPC patients may already be on other medications due to comorbidities. This scheme will help you to assess the drug interaction with ARPIs.

Hit early. Hit hard. Think Nubeqa

NUBEQA® - Built for the long term
14

Swiss Consensus Recommendations

A majority (60%) of the Swiss Consensus Board of SCI recommends for high volume mHSPC patients a triplet 
with ADT + docetaxel + ARPI.

ADT: androgen deprivation therapy, ARPI: androgen receptor pathway inhibitor

* In the overall population, the primary endpoint of overall survival was achieved with triplet therapy compared to docetaxel and ADT alone: HR: 0.675; 95% CI: 0.568–0.801; p<0.0001. The secondary endpoint related to time to CRPC compared to docetaxel and ADT alone: HR: 0.357; 95% CI: 0.302–0.421; p<0.0001. (4)

References:

  1. Templeton AJ, et al. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss Med Wkly 2023;153:40108.
  2. Hoeh B, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. Eur Urol Focus 2023;9(5):838–842.
  3. Swiss specialist information NUBEQA® , www.swissmedicinfo.ch, As of 07/24.
  4. Hussain M, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol 2023;41(20):3595–3607.
  5. Smith MR, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 2022;386:1132–1142.
  6. FOPH specialty list, www.spezialitaetenliste.ch, last accessed March 2025.
  7. Turco F et al. Safety profile of darolutamide versus placebo: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 2024 Sep;27(3):385-392.
  8. Fachinformation Schweiz Zytiga (Arbirateron): www.swissmedicinfo-pro.ch.
  9. Bolek H, et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open 2024;9(11):103736.
  10. Bourjonnier F et al. Pharmacokinetic Interactions Between Abiraterone, Apalutamide, Darolutamide or Enzalutamide and Antithrombotic Drugs: Prediction of Clinical Events and Review of Pharmacological Information. Cardiovascular Drugs and Therapy (2024) 38:757–767.
  11. Fachinformation Schweiz Erleada (Apalutamid): www.swissmedicinfo-pro.ch.
  12. Fachinformation Schweiz Xtandi (Enzalutamid): www.swissmedicinfo-pro.ch.
  13. Carles J et al. Age-related efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subgroup analysis of ARASENS. Poster presentation at ASCO-GU, 2025.02.13, poster D17.
  14. Shore N, Tombal B, Hussain M, Saad F, Fizazi K, Alekseev B, et al. IP26-06 Long-term Safety and Tolerability of Extended Treatment with Darolutamide in Metastatic Hormone-sensitive Prostate Cancer (mHSPC): Insights fraom ARASENS Rollover Study. J Urol [Internet] 2025.05.01 [cited 2025 May 9];213(5S):e1359. Available from: https://doi.org/10.1097/01.JU.0001110200.18879.65.06.

All references can be ordered at onko.ch@bayer.com.